Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Drug Manufacturers - Specialty & Generic

Healthcare
$1.50 +1047.56%

+$7.31 today

Market cap
$71.09M
Beta
-2.17
P/E (TTM)
-36.3
EPS (TTM)
-$1.50
52W Low $0.62High $13.08

Volume 0.02M

Average 0.10M

ZYBT Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Zhengye Biotechnology Holding LimitedNASDAQ: ZYBT

Net Debt · Q4 FY2025 · quarter ended Dec 2025

Net debt falls 63.5% from a year ago

Net debt stood at CN¥24.75M at the end of Q4 FY2025, down 63.5% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at -23.4% a year.

Context

  • Net debt amounted to 5.7% of total assets at the end of Q4 FY2025, down 8.1 pp from a year earlier.
  • Net debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -63.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
CN¥24.75M+0.0% QoQ
Last fiscal yearDec 2025
CN¥24.75M-63.5% YoY
Year agoDec 2024
CN¥67.83M-63.5% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-63.5%——
1 year-63.5%——
3-year CAGR-23.4%——
5-year CAGR——
10-year CAGR——

Net Debt history

CNY · from the balance sheet

Latest · FY2025
24.75M CNY
Year-over-year change
-63.5%
4-year CAGR
+1.1%

Net Debt vs competitors

How ZYBT compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -63.5% is the lowest of 9, against a peer median of +8.9%.
  • Net debt amounts to 5.7% of total assets for ZYBT, versus a peer median of 26.8%.
ZYBT Competitors
Net Debt for ZYBT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TILInstil Bio, Inc.Mar 2026$80.16M USD+12.4%+29.5%40.0%
ZYBTZhengye Biotechnology Holding LimitedDec 2025CN¥24.75M CNY-63.5%-23.4%5.7%
PDEXPro-Dex, Inc.Mar 2026$10.18M USD-32.7%+2.2%13.6%
APYXApyx Medical CorporationMar 2026$8.32M USD+5.3%—13.2%
EXOZeXoZymes, Inc.Mar 2026-$279.68K USD+96.1%—7.0%
SERASera Prognostics, Inc.Mar 2026-$1.67M USD+64.2%—1.8%
ONCYOncolytics Biotech Inc.Mar 2026-CA$4.99M CAD+65.1%—61.1%
CRDLCardiol Therapeutics Inc.Mar 2026-CA$27.63M CAD-19.4%—87.7%
SRZNSurrozen, Inc.Mar 2026-$100.13M USD-6.9%—83.0%
Peer median (excluding ZYBT) —+8.9%+15.9%26.8%

Competitors are the stored peer set for ZYBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents6.28M9.75M15.07M18.6M50.33M
Short-term Investments001.22M1.43M1.56M
Net Receivables102.19M134.25M99.42M88.52M18.49M
Inventory43.62M55.42M58.3M58.22M39.17M
Other Current Assets11.14M12.46M24.03M2K6.78M
Total Current Assets164.94M214.31M205.59M177.57M137.42M
Property, Plant & Equipment (Net)255.12M283.67M271.5M255.16M237.28M
Goodwill00000
Intangible Assets12.05M19.46M16.3M22.78M54.76M
Long-term Investments00000
Tax Assets00010.99M0
Other Non-current Assets13.17M2.23M6.5M26.75M7.01M
Total Non-current Assets280.34M305.37M294.3M315.68M299.05M
Total Assets445.28M519.67M499.89M493.25M436.47M
Account Payables77.57M79.28M45.66M42.96M44.01M
Short-term Debt30M54.89M79.86M81.63M65.8M
Tax Payables6.81M10M2.3M2.07M2.35M
Deferred Revenue4.28M4.7M3.99M3.69M4.83M
Other Current Liabilities0003.28M397K
Total Current Liabilities125.63M152.23M150.23M135.91M120.48M
Long-term Debt09.99M9.99M4.8M8.85M
Deferred Tax Liabilities0000104K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities816K590K393K00
Total Non-current Liabilities816K10.58M10.38M4.8M9.28M
Total Liabilities126.44M162.81M160.62M140.71M129.76M
Common Stock8K8K8K8K8K
Retained Earnings42.33M65.77M38.38M48.15M(21.63M)
Accumulated OCI21.99M27.57M31.31M32.65M30.72M
Other Stockholders Equity00000
Minority Interest51.36M60.37M66.42M68.58M56.87M
Total Equity318.84M356.87M339.27M352.54M306.72M
Total Debt30M64.88M89.85M86.43M75.08M
Net Debt23.72M55.13M74.78M67.83M24.75M

Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Intrinsic Alpha fair value

Locked

Current Price

$1.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.